Tocilizumab in patients with adult-onset still’s disease refractory to glucocorticoid treatment: a randomised, double-blind, placebo-controlled phase III trial

Yuko Kaneko; Hideto Kameda; Kei Ikeda; Tomonoti Ishii; Kosaku Murakami; Hyota Takamatsu; Yoshiya Tanaka; Takayuki Abe; Tsutomu Takeuchi

doi:10.1136/annrheumdis-2018-213920

Article info

Clinical and epidemiological research

Tocilizumab in patients with adult-onset still’s disease refractory to glucocorticoid treatment: a randomised, double-blind, placebo-controlled phase III trial

Free

Authors

Yuko Kaneko Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan PubMed articles Google scholar articles
Hideto Kameda Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan Division of Rheumatology, Department of Internal Medicine, Toho University Ohashi Medical Center, Tokyo, Japan PubMed articles Google scholar articles
Kei Ikeda Department of Allergy and Clinical Immunology, Chiba University Hospital, Chiba, Japan PubMed articles Google scholar articles
Tomonoti Ishii Department of Hematology and Rheumatology, Tohoku University Graduate School of Medicine, Sendai, Japan PubMed articles Google scholar articles
Kosaku Murakami Department of Rheumatology and Clinical Immunology, Kyoto University, Kyoto, Japan PubMed articles Google scholar articles
Hyota Takamatsu Department of Respiratory Medicine and Clinical Immunology, Graduate School of Medicine, Osaka University, Osaka, Japan PubMed articles Google scholar articles
Yoshiya Tanaka The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan PubMed articles Google scholar articles
Takayuki Abe Department of Preventive Medicine and Public Health, Biostatistics at Clinical and Translational Research Center, Keio University School of Medicine, Tokyo, Japan PubMed articles Google scholar articles
Tsutomu Takeuchi Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan PubMed articles Google scholar articles

Citation

Kaneko Y, Kameda H, Ikeda K, et al

Tocilizumab in patients with adult-onset still’s disease refractory to glucocorticoid treatment: a randomised, double-blind, placebo-controlled phase III trial

Annals of the Rheumatic Diseases 2018;77:1720-1729.

Publication history

Received June 11, 2018
Accepted August 8, 2018
First published October 2, 2018.

Online issue publication

November 16, 2018

Article Versions

Previous version (16 November 2018).
You are viewing the most recent version of this article.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Main menu

Authors

Citation

Publication history

Article Versions

Request permissions

Copyright information

Log in using your username and password

Main menu

Log in using your username and password

You are here

Authors

Citation

Publication history

Article Versions

Request permissions

Copyright information

Read the full text or download the PDF:

Log in using your username and password